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Objective: The Hartley guinea pig develops articular cartilage degeneration similar to that seen in
idiopathic human osteoarthritis (OA). We investigated whether the application of pulsed low-intensity
ultrasound (PLIUS) to the Hartley guinea pig joint would prevent or attenuate the progression of this
degenerative process.
Methods: Treatment of male Hartley guinea pigs was initiated at the onset of degeneration (8 weeks of
age) to assess the ability of PLIUS to prevent OA, or at a later age (12 months) to assess the degree to
which PLIUS acted to attenuate the progression of established disease. PLIUS (30 mW/cm2) was applied
to stiﬂe joints for 20 min/day over periods ranging from 3 to 10 months, with contralateral limbs serving
as controls. Joint cartilage histology was graded according to a modiﬁed Mankin scale to evaluate
treatment effect. Immunohistochemical staining for interleukin-1 receptor antagonist (IL-1ra), matrix
metalloproteinase (MMP)-3, MMP-13, and transforming growth factor (TGF)-b1 was performed on the
cartilage to evaluate patterns of expression of these proteins.
Results: PLIUS did not fully prevent cartilage degeneration in the prevention groups, but diminished the
severity of the disease, with the treated joints showing markedly decreased surface irregularities and
a much smaller degree of loss of matrix staining as compared to controls. PLIUS also attenuated disease
progression in the groups with established disease, although to a somewhat lesser extent as compared to
the prevention groups. Immunohistochemical staining demonstrated a markedly decreased degree of
TGF-b1 production in the PLIUS-treated joints. This indicates less active endogenous repair, consistent
with the marked reduction in cartilage degradation.
Conclusions: PLIUS exhibits the ability to attenuate the progression of cartilage degeneration in an animal
model of idiopathic human OA. The effect was greater in the treatment of early, rather than established,
degeneration.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Osteoarthritis (OA) is a slowly progressive, highly prevalent,
degenerative disease of diarthrodial joints which leads to loss of
normative articular cartilage structure and function. WhileRichard G. Spencer, Magnetic
National Institute on Aging,
n Shock Drive, Baltimore, MD
8.
er).
Ltd on behalf of Osteoarthritis Reprogress has been made, the search for a clinically useful disease-
modifying drug for OA remains ongoing1–3. A different approach is
suggested by the well-established fact that appropriate mechan-
ical input acts as an anabolic stimulus to chondrocyte metabolism
and matrix production4–9. While readily implemented in in vitro
cartilage studies, mechanical input can be difﬁcult to apply to an
animal or human joint. A convenient mode of implementing
mechanical stimulation of cartilage is through low-intensity
ultrasound. A number of studies have found an ultrasound-
induced increase in aggrecan gene expression and chondroitin
sulfate synthesis; the systems studied include chondrocytes har-
vested from embryonic chick sterna10; chondrocytes from thesearch Society International.
Table I
Description of experimental groups
Early or late
intervention
Age at enrollment
for treatment
Duration of
treatment
Age at histologic
evaluation
Group E2/T4,
n¼ 8
Early 2 months 4 months 6 months
Group E2/T10,
n¼ 8
Early 2 months 10 months 12 months
Group E12/T3,
n¼ 7
Late 12 months 3 months 15 months
Group E12/T6,
n¼ 8
Late 12 months 6 months 18 months
Group designations indicate age of animal when enrolled for treatment and dura-
tion of treatment, in months. One animal in group E2/T4 died after 11 weeks of
treatment; data included. One animal in group E12/T3 died early in the course of
treatment and was not evaluated.
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the healing fracture callus in the rat13; cells harvested from
bovine14 or rabbit15 intervertebral disc; chondrocytes obtained
from human OA patients16; and cultured explants from embryonic
chick sterna17 and from human joints18. Type II collagen
augmentation has also been found in several of these ultrasound-
stimulated systems10,14,16–18. This is of particular interest due to
the low collagen-to-proteoglycan ratio typical of engineered
cartilage constructs19.
Ultrasound has also been applied to animal models of degen-
erative cartilage lesions. In two studies20,21 knee cartilage
degeneration was induced in the rat by injection of papain. It was
found that cartilage repair was enhanced by ultrasound exposure
in cases of mild pathology, while progression of established
disease was attenuated. In another study, an acute chemical
arthritis was induced in the radiocarpal joint of calves by intra-
articular injections of turpentine oil22. Again, the effect of ultra-
sound applied over the joint was to improve the histologic state of
the cartilage. Salutary effects of ultrasound were similarly
observed in donkeys23. Further, it was found that application of
ultrasound to surgically-induced full-thickness osteochondral
lesions in the rabbit knee resulted in a statistically signiﬁcant
improvement in joint pathology and in the histology of repair
cartilage24. Finally, ultrasound in conjunction with high-molecular
weight hyaluronate was found to be effective in reducing OA
pathology in a rabbit model25.
Ultrasound signals incorporating a variety of pulse and power
parameters were used in these in vitro and in vivo studies, but in
general, the power applied was considerably lower than that used
in physical therapy applications26–28.
The animal studies of ultrasound therapy for OA performed to
date have limited relevance to human idiopathic OA due to the
artiﬁcial nature of the induced arthritic lesions. In contrast, the
Hartley guinea pig is known to develop a progressive osteoarthritic
pathology over a period of approximately 2 years that is similar in
many respects to that which develops in humans over decades29–32.
Thus, it is a particularly appropriate model with which to study the
potential effects of therapeutics on idiopathic OA33–36.
The aim of the current study was, therefore, to examine the
efﬁcacy of pulsed low-intensity ultrasound (PLIUS) in the preven-
tion and treatment of idiopathic age-associated OA in the guinea
pig. PLIUS was applied to guinea pigs at early and at more advanced
stages of the development of OA, with efﬁcacy assessed through use
of a histologic scoring system. In a subset of samples, immunohis-
tochemical studies were also performed to provide semi-
quantitative analysis of the expression of proteins of particular
importance in the pathogenesis of OA.
Materials and methods
Experimental groups
A total of 32 outbred male Hartley guinea pigs, forming four
groups of eight animals each, were used in these studies (Table I).
For groups E2/T4 and E2/T10, animals were entered into treat-
ment at 2 months of age, with ultrasound applied for 4 and 10
months, respectively. This is prior to the development of macro-
scopically evident OA based on literature studies, so that this
represented a disease prevention protocol. For groups E12/T3 and
E12/T6, animals were entered into treatment at 12 months of age,
with ultrasound applied for 3 and 6 months, respectively. Appli-
cation of PLIUS to these groups represented treatment of estab-
lished disease. PLIUS was applied externally for 20 min per day to
the medial aspect of the left knee of all animals while they were
gently restrained in a custom-built harness as described below.The contralateral limb was used as a control in order to account
for the substantial interanimal variability in the development of
OA in this model. Accordingly, care was taken to handle both
limbs equivalently.Ultrasound therapy and test device description
PLIUS treatment
PLIUS was generated using the Sonic Accelerated Fracture
Healing System (SAFHS; Smith and Nephew, Inc., Memphis, TN),
with an intensity of 30 mW/cm2 (spatial average-temporal average;
SATA) and a sinusoidal waveform of frequency 1.5 MHz. The pulse
burst frequency was 1 kHz and the burst durationwas 200 ms. After
sedation with 5 mg/kg xylazine and 35 mg/kg ketamine, legs were
shaved and the animals were immobilized on home-built supports
permitting full access to their limbs. Ultrasound transducers were
attached to the supports and ﬁxed to the medial aspect of the left
knee. Standard coupling gel was applied between the transducer
head and the limb to minimize reﬂection and attenuation of the
ultrasound energy. The right knees were handled in an equivalent
manner but were shielded from the transducer by a plastic barrier.
The duration of PLIUS exposurewas 20 min per day, 5 days/week, in
conformity with the standard protocol for the PLIUS device when
used for bone fracture healing37.Sample preparation
Sedated animals were sacriﬁced by the administration of
intravenous KCl, 0.5 mg/kg body weight. Right and left knees were
harvested intact and were placed in neutral buffered formalin
prior to histologic analysis. Decalciﬁcation was initiated by
repeated rinsing with phosphate buffered saline (PBS) for 60 min,
followed by immersion in formic acid. Uniform exposure was
ensured by agitation of the samples. After complete decalciﬁca-
tion, the knees were processed with EtOH and xylenes, followed
by parafﬁn embedding. Sections were prepared with a thickness
of 6 mm and were stained with 0.1% thionin, a metchromatic stain
that is sensitive primarily to the glycosaminoglycan component of
the matrix, for histologic analysis. We have found thionin to
exhibit particularly stable staining characteristics with respect to
sample variations, including hydration38,39. All compared sections
(treated vs control) were stained in the same batch to control
insofar as possible for variability in the process. The ﬁxation and
sectioning process was performed with the joints articulated and
intact.
Table II
Modiﬁed Mankin scoring scale
Fibrillation 1. Even surface
2. Uneven surface
3. Fibrillated and ﬁssured within superﬁcial zone only
4. Fissures and erosions extending below the surface
zone, without extending beyond the radial zone
5. Fissures and erosions extending into the deep zone
Matrix distribution 1. Normal staining
2. Moderate loss in staining
3. Severe loss in staining
4. No staining
Chondrocyte loss 1. Loss extending into superﬁcial zone
2. Loss extending into mid-zone
3. Loss extending into radial zone
Chondrocyte cloning 1. No clusters
2. Chondrocyte clusters in superﬁcial zone
3. Chondrocyte clusters in superﬁcial to mid-zone
(less than four cells)
4. Chondrocyte clusters of more than four cells located
in superﬁcial to mid-zone, or chondrocyte clusters in
deep zone
Grading was performed separately for the medial femoral condyle, lateral femoral
condyle, medial tibial plateau, and lateral tibial plateau. Minimum total score is 4
and maximum total score is 16.
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Microscopic joint pathology was assessed at several sites in the
femorotibial joint according to a histological grading system (Table
II) modiﬁed from Mankin40. Fibrillation, matrix distribution and
staining, chondrocyte loss, and chondrocyte cloning were assessed
by two independent observers blinded to treatment group, with
reported scores representing consensus. Images were obtained
with a 4 ﬁxed objective.Immunohistochemical analysis
Knees were dissected and tissue was processed, embedded, and
sectioned according to standard procedures. Antigens were
unmasked by treating sections with 0.1 units/mL chondroitinase
ABC (Sigma, St. Louis, MO) for 30 min at 37C. The following anti-
bodieswereused: (1) interleukin-1 receptor antagonist (IL-1ra; R&D
Systems, Inc., Minneapolis, MN, # AF-480-NA), at a 1:50 dilution for
a ﬁnal concentration of 2 mg/mL; (2) matrix metalloproteinase
(MMP)-3 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, # SC-6839),
at a 1:100 dilution for a ﬁnal concentration of 2 mg/mL; (3) MMP-13Table III
Modiﬁed Mankin scores for tibial plateau
Medial tibial plateau Lateral t
Right knee: control Left knee: PLIUS Right kn
Group E2/T4y 8.12 1.08 7.45 0.81* 7.18 1.
Group E2/T10 10.12 1.49 9.49 0.68 7.70 0.
Group E12/T3 10.03 1.58 9.41 1.29 8.08 0.
Group E12/T6 10.78 1.22 10.79 1.11 8.15 0.
Groups E2/T4þ E2/T10 9.12 1.67 8.47 1.28* 7.44 0.
Groups E12/T3þ E12/T6 10.43 1.40 10.15 1.35 8.12 0.
Statistical comparisons are between control and treated knees. Bold indicates statistical
ences (&P< 0.10).
y E2/T4 indicates animals for which treatment was initiated at 2 months of age and app
combined groups E2/T4þ E2/T10 indicate the efﬁcacy of PLIUS for disease prevention ove
for treatment of established disease. Values shown are mean MMS SD.(SantaCruzBiotechnology,#SC-12363), at a1:100dilution foraﬁnal
concentration of 2 mg/mL; and, (4) transforming growth factor
(TGF)-b1 (Santa Cruz Biotechnology, # SC-146), at a 1:100 dilution
for a ﬁnal concentration of 2 mg/mL. Femoral condyle tissue was
exposed to primary antibody overnight at 37C. Secondary antibody
staining and visualization was performed using the ABC system
(SantaCruzBiotechnology). Thepercentageof cells showingpositive
staining for antibodies was evaluated using Bioquant Nova v5.00.8
software (R&M Biometrics, Nashville, TN).Statistical comparisons
Numerical data are given as mean SD. Comparison of differ-
ences between modiﬁed Mankin scores (MMSs) for control and
PLIUS-treated limbswas performed using theWilcoxon signed rank
test. Comparisons of percent of cells showing positive staining for
IL-1ra, MMP-13, and MMP-3 between treated and contralateral
limbs were performed using the two-tailed Student’s t test for
paired data. Statistical signiﬁcance was taken as P< 0.05 in all
cases.Results
As noted, treatment of groups E2/T4 and E2/T10 represented
early intervention (prevention), while treatment of groups E12/T3
and E12/T6 represented treatment of more established disease.Histology
Progression of OA in untreated limbs
As expected, the MMSwas observed to increase over time in the
untreated limbs (Tables III and IV), consistent with the known
progression of OA in the guinea pig41. The greatest progression
occurred in the medial tibial plateau, where the MMS increased
from 8.121.08 at 6 months to 10.78 1.22 at 18 months, an
increase of 33% (P< 0.001). In the lateral tibial plateau, the increase
was 7.18 1.00 to 8.15 0.80, a 14% change (P¼ 0.05). The MMS for
the medial femoral condyle was 7.011.01 at 6 months, which
increased to a maximum of 8.39 0.96 at 15 months, a 19.7%
increase (P¼ 0.014). The corresponding values for the lateral
femoral condyle, 6.351.03 at 6 months and 7.22 0.75 at 15
months, a 13.7% change, also showed a trend toward progression
(P¼ 0.074).ibial plateau Average tibial plateau
ee: control Left knee: PLIUS Right knee: control Left knee: PLIUS
00 7.10 0.99 7.65 0.84 7.28 0.77 &
83 7.15 0.55* 8.91 0.54 8.32 0.38*
53 7.69 0.50 9.05 0.94 8.55 0.61
80 8.14 1.30 9.46 0.78 9.47 1.03
95 7.13 0.78 & 8.28 0.96 7.80 0.80**
66 7.93 1.00 9.27 0.85 9.04 0.96
ly signiﬁcant differences (**P< 0.01; *P< 0.05) or trends towards signiﬁcant differ-
lied for 4 months, and similarly for the other group designations. The results for the
rall, while results for the combined groups E12/T3þ E12/T6 indicate overall efﬁcacy
Table IV
Modiﬁed Mankin scores for femoral condyle
Medial femoral condyle Lateral femoral condyle Average femoral condyle
Right knee: control Left knee: PLIUS Right knee: control Left knee: PLIUS Right knee: control Left knee: PLIUS
Group E2/T4y 7.01 1.01 6.77 0.94 6.35 1.03 6.17 0.99 6.68 0.92 6.47 0.82
Group E2/T10 7.67 0.93 7.57 0.47 7.10 0.59 7.61 0.84 7.39 0.66 7.59 0.60
Group E12/T3 8.39 0.96 7.81 0.43 7.22 0.75 6.99 0.76 7.81 0.66 7.40 0.42
Group E12/T6 8.09 1.81 7.97 1.10 7.1 0.78 5.40 1.05** 7.59 1.17 6.83 0.98 &
Groups E2/T4þ E2/T10 7.34 1.00 7.17 0.83 6.73 0.90 6.89 1.15 7.03 0.86 7.03 0.90
Groups E12/T3þ E12/T6 8.24 1.39 7.89 0.83 7.16 0.74 6.14 1.22** 7.70 0.92 7.07 0.77*
Statistical comparisons are between control and treated knees. Bold indicates statistically signiﬁcant differences (**P< 0.01; *P< 0.05) or trends towards signiﬁcant differ-
ences (&P< 0.10).
y E2/T4 indicates animals for which treatment was initiated at 2 months of age and applied for 4 months, and similarly for the other group designations. The results for the
combined groups E2/T4þ E2/T10 indicate the efﬁcacy of PLIUS for disease prevention overall, while results for the combined groups E12/T3þ E12/T6 indicate overall efﬁcacy
for treatment of established disease. Values shown are mean MMS SD.
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Representative histologic ﬁndings are shown in Figs. 1–4. The
ﬁgures are oriented with the femoral condyle above the tibial
plateau, and each shows the control and PLIUS-treated knees for
one animal. The effect of PLIUS treatment on group E2/T4 is shown
in Figs. 1 and 2. Although the pathology was relatively modest even
in the medial compartment of this group, the control knees
demonstrated surface ﬁbrillation, ﬁssuring, and loss of matrix
staining, particularly in themedial tibial plateau (Fig. 1). The degree
of pathologic change was decreased in the PLIUS-treated knees. In
the lateral compartment as well (Fig. 2), surface irregularities and
staining deﬁcits were seen in the control limbwhich were not seen
in the PLIUS-treated knee. Figure 3 shows an example of PLIUS
treatment for group E2/T10. In themedial compartment (Fig. 3), the
tibial plateau of the treated limb shows moderate staining loss
similar to that seen in the femoral condyle of the untreated limb,
but the untreated knee demonstrates a greater degree of surface
irregularities as well as more pathologic changes in both the tibial
plateau and femoral condyle. In the lateral compartments of group
E2/T10 the effect of treatment with PLIUS to attenuate the devel-
opment of OA was also readily observed, with the control knees
demonstrating greater morphologic irregularities and staining lossFig. 1. Group E2/T4, medial compartment. Thionin stain. A. Left side, PLIUS treated. Medial
Medial femoral condyle: Intact surface with uniform matrix staining. B. Right side, control.
superﬁcial loss of matrix staining. Medial femoral condyle: intact surface with moderate lothan the PLIUS-treated knees. For group E12/T6, a greater degree of
surface irregularity, ﬁssuring, and staining loss in the medial
compartment of the tibial plateau of the untreated limbs was again
seen. Figure 4 illustrates the effects of treatment in the lateral
compartment of that group for an animal with relatively mild OA.
Again, there are more pronounced morphologic irregularities and
staining loss in the control limb. Treatment effects were also seen in
the limbs of animals with much more severe disease; staining loss
and ﬁssuring are seen in both the control and PLIUS-treated limbs
in these animals with more advanced disease but the deﬁcits are
more pronounced in the control limb. Similar results were obtained
for group E12/T3.
Tables III and IV show averaged values for the MMS for the tibial
plateau and femoral condyle, respectively, for the control and
PLIUS-treated animals.
As shown in Table III, the effectiveness of PLIUS therapy was
particularly evident in the medial tibial plateau of group E2/T4 and
the lateral tibial plateau of group E2/T10. The greatest efﬁcacy was
seen when the data for the prevention groups, E2/T4 and E2/T10,
were combined. For the overall prevention group, indicated in Table
III by ‘‘groups E2/T4þ E2/T10’’, there was a statistically signiﬁcant
therapeutic effect of PLIUS treatment for the medial tibial plateau,tibial plateau: intact surface with mild loss of matrix staining in the superﬁcial region.
Medial tibial plateau: extensive surface ﬁbrillation with ﬁssuring to the deep zone and
ss of matrix staining.
Fig. 2. Group E2/T4, lateral compartment. Thionin stain. A. Left side, PLIUS treated. Tibial plateau: intact surface, no loss of staining. Femoral condyle: intact surface, no loss of
staining. B. Right side, control. Tibial plateau: extensive surface irregularities with mild loss of matrix staining. Femoral condyle: intact surface, no loss of staining. C and D.
Expansion of indicated regions of Panels A and B.
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signiﬁcant improvement in MMS for the averaged tibial plateau
scores.
The results shown in Table IV demonstrate that the ability of
PLIUS to attenuate the progression of established disease was
particularly evident in the lateral femoral condyles of group E12/T6.
For the overall treatment of established disease, as seen by the
combined results for ‘‘groups E12/T3þ E12/T6’’ in Table IV, thereFig. 3. Group E2/T10, medial compartment. Thionin stain. A. Left side, PLIUS treated. Tibial p
minimal matrix staining loss. B. Right side, control. Tibial plateau: small surface irregularitywas a statistically signiﬁcant treatment effect seen in the lateral
compartment and for the averaged medial condyle scores. Of note
is that in no case did the treated limb demonstrate a trend toward
a greater MMS.
Immunohistochemistry
Samples from eight animals (group E2/T4) were analyzed for
the percent of chondrocytes expressing MMP-3 (stromelysin-1),lateau: intact surface with moderate staining loss. Femoral condyle: intact surface with
. Femoral condyle: ﬁssuring to the middle zone and moderate loss of matrix staining.
Fig. 4. Group E12/T6, Lateral compartment. Thionin stain. A. Left side, PLIUS treated. Lateral tibial plateau: intact surface and staining. Lateral femoral condyle: intact surface and
staining. B. Right side, control. Lateral tibial plateau: ﬁssuring to middle zone with focal mild matrix staining loss. Lateral femoral condyle: intact surface and uniform staining. C and
D. Expansion of indicated regions of Panels A and B.
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of knees exposed to the PLIUS treatment as compared to the
contralateral control knee (Figs. 5 and 6). For IL-1ra, four animals
showed increased expression on the treated side and the other
four animals showed decreased expression; there was no differ-
ence on average between the treated and untreated limbs. In the
case of MMP-3, there was no consistent pattern observed, with
three animals showing increased expression in the treated carti-
lage and ﬁve animals showing decreased expression. Overall,Immunostaining Results, Group E2/T4
0
5
10
15
20
25
30
35
40
IL1-RA MMP-3 MMP-13
%
 
C
e
l
l
s
 
S
t
a
i
n
i
n
g
 
P
o
s
i
t
i
v
e
Left (treated) leg
Right (control) leg p = 0.075 p = 0.012
Fig. 5. Percent of cells showing positive staining for IL-1ra, MMP-3, and MMP-13 in
group E2/T4. On average, PLIUS treatment resulted in a trend for a smaller percentage
of cells to express MMP-3, and a statistically signiﬁcant reduction in the percentage of
cells expressing MMP-13.however, there was a trend to a smaller average MMP-3 value in
the treated limbs (P¼ 0.075). In contrast to these mixed results, the
percentage of cells expressing MMP-13 was lower in the PLIUS-
treated side as compared to the control side in all eight animals
studied, with a statistically signiﬁcant difference being observed
between the two sides (P< 0.02).
A further striking effect of PLIUS treatment was observed on the
expression level of TGF-b1. In all eight animals of group E2/T4,
TGF-b1 was widely expressed by chondrocytes throughout the full
extent of the articular cartilage of the femoral condyles of control
limbs (Fig. 6). Figure 6(A) shows a typical example of the wide-
spread expression of TGF-b1 throughout the articular surface of
a non-treated joint. The expression of TGF-b1 was often observed
associated with chondrocytes found in colonies which are thought
to be part of a repair response [Fig. 6(B); expansion of region of
Fig. 6(A)]. Figure 6(C) shows the widespread expression of TGF-b1
in a non-treated joint from another representative animal. In
contrast, the expression of TGF-b1 was dramatically reduced in the
articular cartilage exposed to the PLIUS treatment; Figure 6(D)
shows the treated joint contralateral to the control joint shown in
Fig. 6(A). In general, the PLIUS-treated articular cartilage displayed
minimal expression of TGF-b1. In both the treated and non-treated
limbs, chondrocytes in the superﬁcial zone showed the highest
level of expression.
Discussion
PLIUS has been applied to a number of in vitro systems and
animal models of OA in an effort to characterize its ability to
Fig. 6. Representative results of immunostaining for TGF-b1 in the femoral condyles of group E2/T4. A. Expression of TGF-b1 is seen throughout the articular surface of non-treated
joint. 4 ﬁxed objective. B. Expansion of region of Panel A. Association of TGF-b1 expression with chondrocytes in clusters. 10 ﬁxed objective. C. Representative region of
a different untreated limb, again indicating widespread TGF-b1 expression. 4 ﬁxed objective. D. Dramatic reduction of TGF-b1 expression seen in articular cartilage exposed to
PLIUS treatment; shown is the treated joint contralateral to the control joint shown in Fig. 6(A). 10 ﬁxed objective. In all animals, PLIUS-treated articular cartilage displayed
minimal expression of TGF-b1.
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cellular studies have indicated that application of PLIUS results in
upregulation of genes involved in anabolic and repair processes,
and production of the corresponding proteins has been shown to
follow. Similarly, the efﬁcacy of PLIUS has been demonstrated in
a number of animal models of localized arthritis. However, to date,
these experiments have all involved application of PLIUS to
artiﬁcially-induced arthritis, whether a focal surgically-induced
lesion, or whole-joint pathology, produced by injection of an irri-
tant into the joint capsule or through disruption of the normal
anatomy of the joint. In contrast, the current study evaluates PLIUS
treatment in the guinea pig model of spontaneous OA, which
closely resembles idiopathic OA in the human.
As expected, even the 6-month old untreated animals demon-
strated OA pathology. The progression of the disease was particu-
larly rapid over the ﬁrst year, with relative stability thereafter.
These results are consistent with previous reports of the natural
history of OA in guinea pigs. In general, OA changes are ﬁrst
observed in the medial tibial plateau at approximately 3 months of
age, and later in the medial femoral condyle at approximately
12–18 months32. Tokuda42 reported femoral condyle changes as
early as 5 months. Lateral tibial plateau lesions are reported to
occur at approximately 30–40 weeks30,42. In the present study, the
extent of these degenerative cartilage changes was attenuated by
ultrasound exposure, especially in the overall prevention groups
and overall treatment groups, as described in detail above.
The most striking ﬁnding from immunostaining was a strong
reduction in TGF-b1 with PLIUS treatment, as seen throughout theimmunohistologic section. Previous studies have investigated the
effects of PLIUS onTGF-b1 production. Mukai43 showed that TGF-b1
production was promoted over a time course of up to 12 h after
application of PLIUS to aggregates of rat chondrocytes harvested
from the distal femur of 2-day-old rats, and that both PLIUS and
direct application of TFG-b1 itself to the culture system resulted in
greater expression of type II collagen and aggrecan mRNA. Appli-
cation of anti-TGF-b1 neutralizing antibody rendered the applica-
tion of PLIUS ineffective. Thus, in this setting, TGF-b1 indicates an
acute repair response. However, in nucleus pulposus cells har-
vested frommature dogs, Hiyama44 found that PLIUS did not result
in an increase in TGF-b1 productionwhen assayed on the same day
as the second of two PLIUS applications. Park et al.45 applied PLIUS
over a period of 5 days to three-dimensional constructs of chon-
drocytes harvested from the knees of 2-week-old pigs, ﬁnding that
TGF-b1 expression was minimally responsive to application of
PLIUS. In our experiments, application of PLIUS extended over
a period of months. The decreased level of TGF-b1 protein
expression seen after 4 months of PLIUS treatment indicates a less
active ongoing repair response; this is consistent with the marked
reduction in cartilage degradation seenwith treatment, resulting in
a much lower requirement for active endogenous repair in the
treated limb as compared to the untreated limb. Further, the results
of immunostaining indicated an overall decrease in MMP-13 with
treatment, consistent with PLIUS acting to attenuate type II
collagen digestion. This contrasts with the results of Park et al.45, in
which the mRNA level of MMP-13 was unchanged with PLIUS
stimulation in, however, a very different experimental protocol.
I. Gurkan et al. / Osteoarthritis and Cartilage 18 (2010) 724–733 731There has been increasing recognition that effective therapeu-
tics for OA may require more than chondroprotection and
repair46,47. In particular, other joint structures besides cartilage,
including bone, synovium, and periarticular muscle, may be
involved in the initiation of OA and may also sustain damage from
the process itself48,49. According to this concept, PLIUS may have
particular potential for OA treatment due to its documented effects
on other tissues in addition to cartilage50,51.
The mechanism by which ultrasound and other forms of
mechanical input provide an anabolic stimulus to cartilage has
been investigated in a number of studies. Activation of integrins
and a downstream Rho/ROCK/Src/ERK signaling pathway were
found to result from PLIUS application to human skin ﬁbroblasts52.
This suggests a mechanism by which PLIUS may accelerate wound
healing and, by extension, increase metabolism in other connective
tissues. A subsequent study of PLIUS in an immortalized chon-
drocyte line identiﬁed the activation of a comparable signaling
pathway accompanied by upregulation of mRNA for type II collagen
and aggrecan53. The central role of integrins in initiating chon-
drocyte mechanotransduction pathways has been extensively
reviewed54,55.
Pulsed electromagnetic ﬁeld (PEMF) therapy has also been
applied to cartilage disease33,56,57. Indeed, clear disease modiﬁca-
tion effects of PEMF in animal models of OA, including the guinea
pig model studied here, have been documented. However, in spite
of some evident success in clinical trials with endpoints of
decreased pain and increased function58–60, no disease-modifying
activity of this intervention in clinical studies has been documented
to date.
Although there are currently no well-accepted disease-modi-
fying interventions for OA, it is generally agreed that treatment of
the disease in its earlier stages is likely to be more effective than
treatment of more advanced pathology. This notion is supported by
the current results, in which treatment of the medial compartment
of the tibial plateau, which demonstrated the most pathology, was
more effective in the groups E2/T4 and E2/T10 groups than in
groups E12/T3 and E12/T6. It is likely that this may be due to
gradual loss of the ability of chondrocytes to produce matrix
molecules with age, although this hypothesis was not tested in the
present study. Current approaches to early detection are centered
on non-invasive MRI studies, although deﬁning the stage of
pathology at which anatomic abnormalities can be visualized using
this approach remains an open question. Other, non-anatomic,
methods for assessing matrix quality by MRI hold a great deal of
promise for detection of early OA61. Non-imaging methodologies
based on synovial ﬂuid and blood markers are also under
development62,63.
There were a number of limitations to this study. It incorpo-
rated a relatively small sample size per treatment group. In spite
of this, the duration of the study permitted the development of
signiﬁcant pathology in the untreated limbs and the emergence of
statistically signiﬁcant treatment effects in the PLIUS limbs. In
addition, virtually all of the non-statistically signiﬁcant results
trended toward efﬁcacy of PLIUS, so that it is likely that a larger
sample size would have resulted in even stronger results. We
further note that selection of an appropriate control group is
problematic for unilateral joint intervention or treatment experi-
ments. Use of a separate group of animals provides a true phys-
iologic control, with outcome measures unaffected by the indirect
effects, such as gait alterations, due to the condition of the index
joint. However, this greatly limits the power of the analysis in the
setting of substantial interanimal variability; this effect was
minimized in our study through choice of the contralateral limb
as control. This choice was also consistent with a conservative
evaluation of treatment efﬁcacy; improvement in the treatedlimbs would be expected to, if anything, limit degeneration in the
contralateral leg. A further limitation is the possibility that
a detailed dose–response investigation of the application of PLIUS
in this OA model may indicate that a different dose or application
regimen is more effective than the one applied. We applied PLIUS
at the dose approved for fracture treatment using the SAFHS. This
dose has been documented to result in anabolic effects on chon-
drocytes and cartilage explants, and in animal models of OA10,17,24.
Limited dose–response data related to this effect is available, with
a doubling of the treatment time from 20 to 40 min/day signiﬁ-
cantly improving the quality of repair tissue in surgically-created
full-thickness osteochondral defects in the rabbit24. It has also
been reported that a reduction in the intensity from 30 mW/cm2
(SATA) to 2 mW/cm2 resulted in further improvement in collagen
gene expression and protein production in chondrocytes isolated
from embryonic chick sterna and cultured in alginate beads10. In
spite of the lack of dose–response data in the current study,
application of the FDA-approved dose was shown to result in the
salutary effects reported. Finally, the present study does not
address the important points of potential effects on bone or
osteophyte formation, and whether the effects of PLIUS would
persist after cessation of the therapy, or whether ongoing treat-
ment is required.
We conclude that PLIUS exhibits clear disease-modifying
activity in an animal model of idiopathic human OA. These results
support the investigation of this modality in a clinical trial.
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